Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Buy" from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been assigned an average rating of "Buy" from the ten research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $12.63.

Several research analysts have issued reports on CATX shares. Truist Financial reduced their price objective on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Royal Bank Of Canada raised Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and upped their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Monday, March 31st.

Perspective Therapeutics Price Performance

Shares of CATX opened at $3.53 on Wednesday. Perspective Therapeutics has a one year low of $1.60 and a one year high of $16.55. The business's 50 day simple moving average is $2.54 and its 200-day simple moving average is $2.85.

Insider Buying and Selling

In other news, CEO Johan M. Spoor purchased 22,026 shares of the company's stock in a transaction on Friday, March 28th. The shares were purchased at an average price of $2.24 per share, with a total value of $49,338.24. Following the purchase, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at $133,017.92. This trade represents a 58.96% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the company's stock in a transaction on Monday, March 31st. The stock was purchased at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the purchase, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This trade represents a 53.85% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 115,696 shares of company stock valued at $256,344. 3.72% of the stock is owned by company insiders.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new position in shares of Perspective Therapeutics in the 4th quarter valued at about $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics in the 4th quarter valued at about $34,000. National Bank of Canada FI grew its holdings in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Perspective Therapeutics by 49.1% in the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after acquiring an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics in the 4th quarter valued at about $51,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.